It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The intestinal immune response is crucial in maintaining a healthy gut, but the enhanced migration of macrophages in response to pathogens is a major contributor to disease pathogenesis. Integrins are ubiquitously expressed cellular receptors that are highly involved in immune cell adhesion to endothelial cells while in the circulation and help facilitate extravasation into tissues. Here we show that specific deletion of the Tln1 gene encoding the protein talin-1, an integrin-activating scaffold protein, from cells of the myeloid lineage using the Lyz2-cre driver mouse reduces epithelial damage, attenuates colitis, downregulates the expression of macrophage markers, decreases the number of differentiated colonic mucosal macrophages, and diminishes the presence of CD68-positive cells in the colonic mucosa of mice infected with the enteric pathogen Citrobacter rodentium. Bone marrow-derived macrophages lacking expression of Tln1 did not exhibit a cell-autonomous phenotype; there was no impaired proinflammatory gene expression, nitric oxide production, phagocytic ability, or surface expression of CD11b, CD86, or major histocompatibility complex II in response to C. rodentium. Thus, we demonstrate that talin-1 plays a role in the manifestation of infectious colitis by increasing mucosal macrophages, with an effect that is independent of macrophage activation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
2 Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University School of Medicine, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
3 Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
4 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University School of Medicine, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
5 Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
6 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
7 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University School of Medicine, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Veterans Affairs Tennessee Valley Healthcare System, Nashville, USA (GRID:grid.452900.a) (ISNI:0000 0004 0420 4633)